价格总表
每个分子的孟加拉注册仿制品牌挂牌单价区间（DGDA/MedEx 数据），并给出原研参考价与节省比例。汇率基准 1 USD = 122.87 BDT。
价格随汇率、包装与药房浮动；不构成报价。点击药品名查看完整资料与分国家价格。
| 药品 | 治疗领域 | 最低单价 | 最高单价 | 30 天最低 | 厂家数 | 原研参考价 | 相对原研 | |
|---|---|---|---|---|---|---|---|---|
| 奥拉帕利 150 mg · AstraZeneca (distributed by AstraZeneca Pharmaceuticals LP); developed and commercialised in collaboration with Merck (MSD outside the US and Canada) | 肿瘤 | BDT 350 US$2.85 | BDT 2,000 US$16.28 | US$85 | 9 | — | — | 价格页 → |
| 劳拉替尼（洛拉替尼） 100 mg · Pfizer Inc. | 肿瘤 | BDT 1,660 US$13.51 | BDT 1,660 US$13.51 | US$405 | 2 | — | — | 价格页 → |
| 克唑替尼 250 mg · Pfizer | 肿瘤 | BDT 350 US$2.85 | BDT 1,500 US$12.21 | US$85 | 7 | — | — | 价格页 → |
| 卡马替尼 200 mg · Novartis (discovered by Incyte, licensed to Novartis in 2009) | 肿瘤 | BDT 1,500 US$12.21 | BDT 1,500 US$12.21 | US$366 | 1 | — | — | 价格页 → |
| 索托拉西布 (索托拉西布/索托雷塞) 120 mg · Amgen | 肿瘤 | BDT 1,000 US$8.14 | BDT 1,500 US$12.21 | US$244 | 2 | — | — | 价格页 → |
| 阿贝西利 200 mg · Eli Lilly and Company (Lilly USA, LLC) | 肿瘤 | BDT 1,150 US$9.36 | BDT 1,150 US$9.36 | US$281 | 3 | — | — | 价格页 → |
| 尼拉帕利 100 mg · GlaxoSmithKline (GSK); originally developed by Tesaro (Tesaro UK Limited) | 肿瘤 | BDT 850 US$6.92 | BDT 1,095 US$8.91 | US$208 | 4 | — | — | 价格页 → |
| 索磷布韦维帕他韦 400 mg+100 mg · Gilead Sciences (Gilead Sciences Ireland UC for the EU) | 抗病毒（丙肝） | BDT 930 US$7.57 | BDT 1,000 US$8.14 | US$227 | 8 | — | — | 价格页 → |
| 伊布替尼 140 mg · Pharmacyclics LLC (an AbbVie company) and Janssen Biotech, Inc. (Johnson & Johnson) - developed and commercialised jointly; US distributor of record: Pharmacyclics LLC | 肿瘤 | BDT 320 US$2.60 | BDT 750 US$6.10 | US$78 | 8 | — | — | 价格页 → |
| 奥希替尼 80 mg · AstraZeneca | 肿瘤 | BDT 333 US$2.71 | BDT 550 US$4.48 | US$81 | 13 | BDT 30,000 US$244.16 | −99% | 价格页 → |
| 阿来替尼 150 mg · Roche (Genentech in the US; originated by Chugai Pharmaceutical) | 肿瘤 | BDT 500 US$4.07 | BDT 500 US$4.07 | US$122 | 1 | BDT 2,082 US$16.94 | −76% | 价格页 → |
| 帕博西尼 125 mg · Pfizer Inc. (Pfizer Laboratories Div Pfizer Inc) | 肿瘤 | BDT 400 US$3.26 | BDT 400 US$3.26 | US$98 | 9 | — | — | 价格页 → |
| 卡格列净 100 mg · Janssen Pharmaceuticals (Johnson & Johnson), licensed from Mitsubishi Tanabe Pharma | 糖尿病与代谢 | BDT 40 US$0.33 | BDT 60 US$0.49 | US$10 | 4 | BDT 75.65 US$0.62 | −47% | 价格页 → |
| 托法替布 5 mg · Pfizer (initial U.S. approval 2012) | 免疫与风湿 | BDT 30 US$0.24 | BDT 48 US$0.39 | US$7 | 15 | — | — | 价格页 → |
| 恩格列净 10 mg · Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH) | 糖尿病与代谢 | BDT 12 US$0.10 | BDT 30 US$0.24 | US$3 | 35 | BDT 69 US$0.56 | −83% | 价格页 → |
| 巴瑞替尼 2 mg · Eli Lilly and Company (co-developed with Incyte; initial U.S. approval 2018) | 免疫与风湿 | BDT 20 US$0.16 | BDT 25 US$0.20 | US$5 | 10 | — | — | 价格页 → |
| 维格列汀 50 mg · Novartis | 糖尿病与代谢 | BDT 12 US$0.10 | BDT 25 US$0.20 | US$3 | 22 | BDT 32 US$0.26 | −62% | 价格页 → |
| 利格列汀 5 mg · Boehringer Ingelheim (marketed in the US by Boehringer Ingelheim Pharmaceuticals, Inc.; co-promoted with Eli Lilly in several markets) | 糖尿病与代谢 | BDT 6 US$0.05 | BDT 25 US$0.20 | US$1 | 39 | — | — | 价格页 → |
| 达格列净 5 mg · AstraZeneca (originally developed with Bristol-Myers Squibb) | 糖尿病与代谢 | BDT 10 US$0.08 | BDT 20 US$0.16 | US$2 | 8 | — | — | 价格页 → |
| 西格列汀 50 mg · Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., Inc. | 糖尿病与代谢 | BDT 13 US$0.11 | BDT 18.05 US$0.15 | US$3 | 20 | — | — | 价格页 → |
| 吡格列酮 15 mg · Takeda Pharmaceutical Company (first US approval 1999) | 糖尿病与代谢 | BDT 5.07 US$0.04 | BDT 8.07 US$0.07 | US$1 | 15 | — | — | 价格页 → |
| 普拉替尼 (普吉华) · Discovered by Blueprint Medicines; co-commercialised with Genentech (Roche) in the US and by Roche ex-US; Blueprint regained global rights (excluding Greater China) in 2023 | 肿瘤 | — | — | — | — | — | — | 价格页 → |
| 贝伐珠单抗 · Genentech, Inc. / F. Hoffmann-La Roche Ltd | 肿瘤 | — | — | — | — | — | — | 价格页 → |
| 曲妥珠单抗 · Genentech, Inc. / F. Hoffmann-La Roche Ltd | 肿瘤 | — | — | — | — | — | — | 价格页 → |
| 利妥昔单抗 · Genentech, Inc. (a member of the Roche Group), with Biogen; Rituxan is jointly marketed by Biogen and Genentech USA in the US; MabThera is marketed by Roche | 肿瘤 | — | — | — | — | — | — | 价格页 → |
| 特立氟胺 · Genzyme Corporation, a Sanofi company (US label lists Genzyme Corporation, Cambridge, MA; Sanofi markets Aubagio) | 免疫与风湿 | — | — | — | — | — | — | 价格页 → |
| 阿达木单抗 · AbbVie (originally developed and marketed by Abbott Laboratories; initial U.S. approval 2002) | 免疫与风湿 | — | — | — | — | — | — | 价格页 → |
| 英夫利昔单抗 · Janssen Biotech / Johnson & Johnson (originally Centocor); initial U.S. approval 1998 | 免疫与风湿 | — | — | — | — | — | — | 价格页 → |
| 利拉鲁肽 · Novo Nordisk | 糖尿病与代谢 | — | — | — | — | — | — | 价格页 → |
| 甘精胰岛素 · Sanofi | 糖尿病与代谢 | — | — | — | — | — | — | 价格页 → |
| 德谷胰岛素 · Novo Nordisk | 糖尿病与代谢 | — | — | — | — | — | — | 价格页 → |
| 门冬胰岛素 · Novo Nordisk | 糖尿病与代谢 | — | — | — | — | — | — | 价格页 → |